AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.
AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.
Funding Rounds (3) - $31MUpdate
ROTH Capital Partners is an investment banking firm dedicated to the small-cap public market.
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences...
BioScience Managers Pty Ltd (formerly IB Managers) is a leading life sciences investment firm,...
Venture capital Firm
800 Leigh Street
Richmond, VA 23219